GENFIT Share Price Other OTC
Stocks
GNFTF
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 720M 840M 673M 617M 1.16B 80.27B 1.18B 7.94B 3.11B 40.26B 3.15B 3.08B 133B | P/E 2026 * |
37.2x | P/E 2027 * | 95.6x |
|---|---|---|---|---|---|
| Enterprise Value | 669M 780M 625M 573M 1.08B 74.57B 1.1B 7.37B 2.89B 37.4B 2.93B 2.87B 124B | EV / Sales 2026 * |
6.68x | EV / Sales 2027 * | 5.27x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -3.28% |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 15/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 21/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 26/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 15/06/2017 | |
| Director/Board Member | 54 | 14/09/1999 | |
| Director/Board Member | 58 | 15/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.28% | -.--% | - | - | 840M | |
| +0.29% | +1.54% | +1.64% | +23.77% | 50.5B | |
| -1.69% | +4.58% | +487.47% | +624.71% | 46.01B | |
| -1.14% | +4.96% | +20.59% | +95.21% | 42.85B | |
| +0.65% | +3.13% | +29.60% | +16.50% | 41.03B | |
| -0.72% | -3.91% | +17.87% | +47.98% | 32.02B | |
| +0.40% | +1.89% | +31.62% | +143.62% | 16.98B | |
| -0.20% | +1.63% | - | - | 17.05B | |
| +1.59% | +2.34% | +4.24% | +33.44% | 14.3B | |
| +0.09% | +1.98% | +82.99% | +45.80% | 13.84B | |
| Average | -0.36% | +2.01% | +84.50% | +128.88% | 30.51B | |
| Weighted average by Cap. | -0.20% | +2.37% | +104.55% | +154.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 100M 117M 93.56M 85.84M 161M 11.16B 164M 1.1B 432M 5.6B 439M 429M 18.51B | 124M 145M 116M 106M 200M 13.82B 203M 1.37B 535M 6.93B 543M 531M 22.92B |
| Net income | 22.88M 26.67M 21.36M 19.6M 36.86M 2.55B 37.46M 252M 98.71M 1.28B 100M 97.96M 4.23B | 6.8M 7.93M 6.35M 5.83M 10.96M 758M 11.14M 74.92M 29.34M 380M 29.77M 29.12M 1.26B |
| Net Debt | -51.12M -59.59M -47.73M -43.79M -82.35M -5.7B -83.71M -563M -221M -2.86B -224M -219M -9.45B | -66.17M -77.14M -61.79M -56.69M -107M -7.37B -108M -729M -286M -3.7B -290M -283M -12.23B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
